Drug Profile
Irdabisant
Alternative Names: CEP-26401Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cephalon
- Developer Teva Pharmaceutical Industries
- Class Nootropics; Pyridazines
- Mechanism of Action Histamine H3 receptor antagonists; Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in Netherlands (PO, Liquid)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in USA (PO, Liquid)
- 01 Dec 2013 Teva Pharmaceutical Industries completes a phase I trial in Cognition disorders (in volunteers) in Netherlands (NCT01903824)